Trade Bristol Myers ^BMY

Regeneron Broadens Pipeline With Ebola Antibody Trials And Bispecific Cancer Bets

CMS Proposes Permanent Framework for Medicare Drug Price Negotiations

Takeda's zasocitinib bests Sotyktu in phase III psoriasis trial | BioWorld

Bristol Myers Squibb Company $BMY Stake Lifted by Xponance LLC

Swiss National Bank Has $300.86 Million Stake in Bristol Myers Squibb Company $BMY

IFM Investors Pty Ltd Raises Stake in Bristol Myers Squibb Company $BMY - Markets Daily

Bristol Myers Squibb Company $BMY Position Raised by Sector Gamma AS - Stock Observer

Bristol Myers Squibb Company $BMY Shares Sold by Colrain Capital LLC

Takeda's AI-Enhanced Psoriasis Pill Outshines Bristol Myers' Sotyktu in Key Trial, ETPharma

Takeda (TAK) Shows Strong Efficacy of Zasocitinib in Psoriasis Trial

Is Arcus Biosciences (RCUS) Using the ROSETTA Trial Tie-Up to Quietly Reframe Its RCC Strategy?

Takeda's TYK2 inhibitor beats BMS' Sotyktu in psoriasis showdown

Deutsche Bank AG Buys 226,088 Shares of Bristol Myers Squibb Company $BMY

M Holdings Securities Inc. Buys Shares of 44,462 Bristol Myers Squibb Company $BMY - Stock Observer

Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor

Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

Camzyos Priority Review And New Oncology Data Could Be A Game Changer For Bristol-Myers Squibb (BMY)

WINTON GROUP Ltd Takes Position in Bristol Myers Squibb Company $BMY - Zolmax

Motley Fool Asset Management LLC Purchases 50,403 Shares of Bristol Myers Squibb Company $BMY - Stock Observer

Bristol Myers Squibb Company $BMY Stock Holdings Raised by Cerity Partners LLC

Cytospire Therapeutics Appoints Samit Hirawat, M.D., as Non-Executive Director

Bristol Myers Squibb Company $BMY Shares Bought by Cerity Partners LLC - Stock Observer

How New Lung Cancer Data for Pumitamig Could Reshape BioNTech's (BNTX) Post-Vaccine Investment Story

Erste Asset Management GmbH Reduces Stock Holdings in Bristol Myers Squibb Company $BMY - Daily Political

[Trending] Cancer Medicine Market Size Expected to Hit USD 279.87 Billion by 2034, With 12.51% CAGR

BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study

Bristol-Myers Squibb Company (BMY) Featured in Citrini's Bullish Healthcare Basket

BMY DCF Analysis: Intrinsic Value $74 vs Price $56

Waddell & Associates LLC Grows Stock Holdings in Bristol Myers Squibb Company $BMY

Bristol Myers Squibb Company $BMY Position Increased by Waddell & Associates LLC - Zolmax

Bristol Myers Squibb Company $BMY Shares Bought by Focus Partners Advisor Solutions LLC - Zolmax

Franklin Resources Inc. Decreases Stock Holdings in Bristol Myers Squibb Company $BMY

Bristol Myers Squibb Company $BMY Shares Acquired by O Shaughnessy Asset Management LLC

Bristol Myers Squibb Company $BMY Shares Acquired by Focus Partners Advisor Solutions LLC

Brandywine Global Investment Management LLC Purchases 52,782 Shares of Bristol Myers Squibb Company $BMY

Mariska Hargitay Partners with Bristol Myers Squibb for "Investigating Myeloma" Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease | Morningstar

Capital International Inc. CA Decreases Stock Position in Bristol Myers Squibb Company $BMY

Bristol Myers Squibb Company $BMY Shares Sold by Capital International Sarl - Daily Political

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial

Real-world outcomes of immunotherapy in advanced NSCLC patients with comorbidities

Forget Wall Street's Ultimate Pharma Value Trap: Here Is a Far Better Stock to Buy Right Now

Vise Technologies Inc. Purchases 18,547 Shares of Bristol Myers Squibb Company $BMY

Vise Technologies Inc. Grows Stock Holdings in Bristol Myers Squibb Company $BMY

Bristol Myers Squibb Company $BMY Position Lessened by TD Asset Management Inc

Bristol Myers Squibb (NYSE:BMY) Downgraded by Wall Street Zen to "Buy"

Assessing Bristol Myers Squibb (BMY) Valuation After Fresh EU Opdivo Approval And New Phase 3 Oncology Data

Bristol Myers Squibb Company $BMY Shares Purchased by Natixis Advisors LLC

WCG Wealth Advisors LLC Has $2.56 Million Holdings in Bristol Myers Squibb Company $BMY - Stock Observer

Cibc World Market Inc. Has $26.92 Million Position in Bristol Myers Squibb Company $BMY

Bristol Myers Squibb Company $BMY Shares Sold by Arrowpoint Investment Partners Singapore Pte. Ltd. - Zolmax

UBS Remains a Buy on Olema Pharmaceuticals (OLMA)

Bristol Myers Squibb Adds New Late Stage Oncology Opportunity With Izalontamab

3 Value Stocks We Think Twice About

Sivia Capital Partners LLC Raises Position in Bristol Myers Squibb Company $BMY

Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation

CIBC Asset Management Inc Buys 196,274 Shares of Bristol Myers Squibb Company $BMY

Bristol Myers Squibb (BMY) Is Down 6.2% After EU Opdivo Frontline Hodgkin Lymphoma Approval - What's Changed - Simply Wall St News

Westpac Banking Corp Purchases 46,386 Shares of Bristol Myers Squibb Company $BMY

Bank of New York Mellon Corp Has $1.32 Billion Stock Position in Bristol Myers Squibb Company $BMY

Rothschild Wealth LLC Purchases New Stake in Bristol Myers Squibb Company $BMY - Daily Political

Westpac Banking Corp Raises Stock Position in Bristol Myers Squibb Company $BMY - Daily Political

BMS patents new CAMK2 inhibitors | BioWorld

Is Bristol-Myers Squibb Stock Underperforming the Dow?

Bristol Myers Squibb Target of Unusually High Options Trading (NYSE:BMY) - Daily Political

Bristol Myers Squibb Target of Unusually High Options Trading (NYSE:BMY)

BMY: Late Stage Milvexian Readouts And Pipeline Wins Will Drive Re Rating

BMY: Positive Interim Results for Bristol Myers' Iza-bren in Can

Is BMY Undervalued? DCF Says Worth $74

BMS' bispecific ADC puts TROP2 drugs on notice

ASCO 2026: Transitioning from PD - 1 Replication to "Defining the Next - Generation Framework" in China's Immunotherapy: Three Routes

Promising Pharmaceutical Stocks To Follow Now - June 1st - Zolmax

Bristol Myers Squibb CEO on $15B deal with China's Hengrui Pharma

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) | Morningstar

Sfmg LLC Decreases Stake in Bristol Myers Squibb Company $BMY

Bristol Myers Squibb CEO warns Australia risks losing access to life-saving medicines, must reform Pharmaceutical Benefits Scheme

MUFG Securities EMEA plc Raises Holdings in Bristol Myers Squibb Company $BMY

Black Swift Group LLC Purchases New Position in Bristol Myers Squibb Company $BMY

Peapack Gladstone Financial Corp Has $24.27 Million Stake in Bristol Myers Squibb Company $BMY - Daily Political

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Evaluating the Clinical and Humanistic Impact of a Self-Care and Minor Ailment Service (MAS)

BMY: Promising Phase 2 Results for Pumitamig in Lung Cancer Treatment

BMY Shows Promising Results in Lung Cancer Trial

Railway Pension Investments Ltd Has $63.89 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Impact Partnership Wealth LLC Cuts Stake in Bristol Myers Squibb Company $BMY - Zolmax

Bristol Myers Squibb Company $BMY Shares Sold by Impact Partnership Wealth LLC

How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks?

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

Illumina Oncology Launches Put Product Depth Against Rapid Share Price Gains

Eurizon Capital SGR S.p.A. Takes $82.35 Million Position in Bristol Myers Squibb Company $BMY - Zolmax

Eurizon Capital SGR S.p.A. Acquires New Holdings in Bristol Myers Squibb Company $BMY

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial | Valuespectrum.com